Recipharm and Astimex Pharma form new development and manufacturing collaboration
Recipharm AB and Astimex Pharma AB have today announced the formation of a collaboration agreement for the development and manufacture of a pharmaceutical product. The formulation development work will take place at the Recipharm pharmaceutical development site located in Solna close to Stockholm. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.
Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects.
Maria Lundberg, General Manager, Recipharm Pharmaceutical Development commented: “I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma have chosen to utilise the expertise and flexible development capabilities that our staff and facilities are able to provide.”
Åsa Lintzen, General Manager, Astimex Pharma AB, said: “We are delighted to be working closely with Recipharm on this specific manufacturing and development project. Indeed, it is Recipharm’s recognised partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility that attracted us in the first place.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.